News Novartis drug gets fast US review in AML Midostaurin also under review in rare disease systemic mastocytosis
News Biogen/Ionis could launch rare disease drug within weeks Companies prepare for launch of Spinraza after phase 3 success.
Views & Analysis Tunnah’s musings: Rare diseases hold key to future of drug d... The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.
Views & Analysis Every voice matters: demand assessment in rare diseases A market research approach suitable for the complexities found in rare diseases.
Views & Analysis Flexible models for better access Which initiatives are the most likely to bring life-changing therapies to patients?
Views & Analysis Digital Health Round-up – pharma to build Moonshot database,... A round-up of this week’s top digital healthcare news. Marco Ricci reports.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
